» Articles » PMID: 14993128

Time Dependence of Mortality Risk and Defibrillator Benefit After Myocardial Infarction

Overview
Journal Circulation
Date 2004 Mar 3
PMID 14993128
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prophylactic implantable defibrillators (ICDs) improve survival in patients with impaired ventricular function after myocardial infarction (MI), but it is uncertain whether mortality risk and survival benefit depend on the elapsed time from MI.

Methods And Results: The Multicenter Automatic Defibrillator Implantation Trial II examined the impact of ICDs on survival in post-MI patients with ejection fractions < or =30%. In 1159 patients, mean time from most recent MI to enrollment was 81+/-78 months. Patients were randomized to an ICD (n=699) or conventional care (n=460) in a 3:2 ratio. Mortality rates (deaths per 100 person-years of follow-up) in both treatment groups were analyzed by time from MI divided into quartiles (<18, 18 to 59, 60 to 119, and > or =120 months). In conventional care patients, these rates increased as time from MI increased (7.8%, 8.4%, 11.6%, 14.0%; P=0.03). Mortality rates in ICD patients were consistently lower in each quartile and showed minimal increase over time (7.2%, 4.9%, 8.2%, 9.0%; P=0.19). Covariate-adjusted hazard ratios for risk of death associated with ICD therapy were 0.97 (95% CI, 0.51 to 1.81; P=0.92) for recent MI (<18 months) and 0.55 (95% CI, 0.39 to 0.78; P=0.001) for remote MI (> or =18 months).

Conclusions: Mortality risk in patients with ejection fractions < or =30% increases as a function of time from MI. The survival benefit associated with ICDs appears to be greater for remote MI and remains substantial for up to > or =15 years after MI.

Citing Articles

Diagnosis and Management of Complex Reentrant Arrhythmias Involving the His-Purkinje System.

Sung R, Boyden P, Higuchi S, Scheinman M Arrhythm Electrophysiol Rev. 2021; 10(3):190-197.

PMID: 34777824 PMC: 8576512. DOI: 10.15420/aer.2021.22.


Predictors of Sudden Cardiac Arrest Among Patients With Post-Myocardial Infarction Ejection Fraction Greater Than 35.

Adabag S, Zimmerman P, Lexcen D, Cheng A J Am Heart Assoc. 2021; 10(14):e020993.

PMID: 34259015 PMC: 8483475. DOI: 10.1161/JAHA.121.020993.


Wearable cardioverter-defibrillators after myocardial infarction: a review of its clinical utility and unmet needs in current clinical practice.

Hioki H, Kozuma K, Kobayashi Y, Ando K, Morino Y, Kishihara J Cardiovasc Interv Ther. 2021; 37(1):53-59.

PMID: 34195951 PMC: 8789717. DOI: 10.1007/s12928-021-00788-1.


Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease.

Boey E, Kojodjojo P J Innov Card Rhythm Manag. 2020; 9(2):3025-3032.

PMID: 32494485 PMC: 7252838. DOI: 10.19102/icrm.2018.090204.


A novel method to enable biventricular defibrillator to biventricular pacemaker downgrade involving DF4 defibrillator lead.

Giedrimas A, Sisson B, Casavant D HeartRhythm Case Rep. 2018; 4(12):598-600.

PMID: 30581741 PMC: 6301893. DOI: 10.1016/j.hrcr.2018.09.006.